What's Hot
View all perspectives
sheila
1 year ago
In a subgrp analysis of the SURPASS study by Dr @XBaraliakos et al, there was low spinal prog over 2 yrs in SEC & SDZ-ADL treated pts regardless of +/- Synd/⬆️CRP
Synd+ > CRP+ as predictor of radiog prog
Again, early dx = early tx
#ACR23 ABST0522 @RheumNow https://t.co/fGF4szPJbp
Dr. Antoni Chan
1 year ago
Higher disease activity and systemic inflammation at baseline associated with greater risk of MACE in bDMARD nonusers but not in users. bDMARD-specific benefits directly on MACE risk beyond reducing inflammation, Karpouzas et al Abst#0391 #ACR23 @RheumNow https://t.co/lfoccZffTW https://t.co/ASpKYQof1I
Dr. John Cush RheumNow
1 year ago
Good Treatment review of biologics (IL-1, IL-6) in systemic JIA (Stills) including complications of #MAS and lung disease; also info on horizon therapies like JAK inhibitors and IL-18 targeting and novel biomarkers (calgranulins, IL-18 and CXCL9) https://t.co/Cbd7bKdIbb https://t.co/d9tn9fmSAy
Robert B Chao, MD
1 year ago
Tofacitinib efficacy and safety in axSpA pts by baseline CRP levels
Elevated CRP pts with higher response in ASAS20, ASAS40, BASDAI50, etc.
AE trended higher in normal CRP pts taking Tofa compared to placebo
@RheumNow #ACR23 Abs#0518 https://t.co/nbiD36x1Pa
Mike Putman EBRheum
1 year ago
Long term safety data for bimekizumab (IL17i) in Psa & axSpA
Overall as expected; increased infections (esp fungal/candida) & hepatic events
No new signals... uveitis flares is interesting
Need H2H of IL17's! IXE vs SEC vs BIM
@RheumNow #ACR23 Abstr 0511 https://t.co/pBqly2JylA
Aurelie Najm
1 year ago
Are anti CCP3 the new anti CCP2 antibodies?
Not yet!
Anti-CCP3 associated w/ diagnosis of RA in a population of patients w/ MSK symptoms
But… very strong overlap between CCP2 and 3 with only 3.4% positive for CCP3 negative for CCP2
@RheumNow #ACR23 ABST 0389 https://t.co/BHRqCbqEYw
Dr. Antoni Chan
1 year ago
Detectable hs-cTnT at baseline was associated with future MACE HR 5.6, in the hsCRP high→low cohort with high inflammation at baseline, not vice versa. hs-cTnT may provide additional info for assessing CV risk, Weber et al, Abst#0387 https://t.co/M4zyz2tzIO #ACR23 @RheumNow https://t.co/omMgpRzBA5
Robert B Chao, MD
1 year ago
Does pregnancy affect axSpA imaging?
Large study of 381 pts, in the DESIR cohort, f/up of 5 years.
Pregnancy did not aggravate imaging of axSpA women compared to prior to pregnancy.
@RheumNow #ACR23 Abs#0513 https://t.co/eeGuxGGB5E
Dr. Rachel Tate
1 year ago
#ACR23 Abs 0465 suggests changes in rheums’ rx patterns in context of nationwide abortion restriction, particularly in abortion-restricted states; reproductive-age female pts may have less access to EB treatments like MTX/MMF for rheum dz. https://t.co/QN9C4PjUaN
@rheumnow
Aurelie Najm
1 year ago
Non invasive screening for pulmonary involvement in early RA
Combination of PFT and Lung 🫁 US:
-50% with interstitial or focal changes or pleural effusion on US
-58% with abnormal DLCO
Correlation w/ higher disease activity.
Pathological meaning?
@RheumNow ABST 0393 #ACR23 https://t.co/BBcOEgcJK2
David Liew drdavidliew
1 year ago
@RheumNow PMR Mythbusters:
we polled Aussie🇦🇺 rheumatologists
How did those motivated enough to answer a PMR/GCA survey fare?
Myth: PMR is only proximal
- not bad
Myth: PMR needs ⬆️ESR/CRP
- a bit of work
Time to #MakeRheumForPMR
@victor_yang1 @CatherineL_Hill #ACR23 ABST0267 https://t.co/Z4ZkDHljOf https://t.co/ssHxOBJFxR
Aurelie Najm
1 year ago
WEAR study: adherence to wearable activity trackers in RA
Something that is consistent across all wearable studies is low adherence
Here under 50% for PRO + tracking
In an already selected population!
To implement, we need to make this better?
ABSTRACT 0344 @RheumNow #ACR23 https://t.co/csVZlzABGt
Dr. Antoni Chan
1 year ago
Difficult to treat D2T-axSpA (failure > 3 biologics), affects one in five patients exposed to b/tsDMARDs in this national registry. D2T is more common in women, presence of peripheral involvement, psoriasis, depression, Fakih O Abst#0514 #ACR23 @RheumNow https://t.co/OoymZzzQST https://t.co/EpTqS1C61A
Mike Putman EBRheum
1 year ago
Deucravacitinib (TYK2) data has been surprisngly good in SLE
Strong rationale in PsA as well; I liked this poster & the focus on pain scores / patient QOL
Probably my #1 draft pick for "drugs I'm buying right now"
@RheumNow #ACR23 Abstr0508 https://t.co/FHNvgUrYxp
Meral K. El Ramahi, MD MeralElRamahiMD
1 year ago
Year in Review: Dr. P Seo
⭐️Does Pizza consumption favor improved dz activity in RA?
If in Italy
➡️ 365 pts w/RA in Milan: 18-65 yo w/ >3 mo dz
➡️Ate 1/2 a pizza > 1x/wk w/ decr in dz activity (SDAI⬇️: -3.6)
➡️Mozzarella & olive oil showed beneficial effects
#ACR23 @RheumNow https://t.co/qZTzThI39e
Poster Hall